Skip to content
TrialScanner

NCT06396065

Phase III Study of AK112 for NSCLC Patients

Phase 3Active, not recruitingSMMTLead

Registry record

Lead sponsor
Summit Therapeutics
Conditions
Non-Squamous Non-small Cell Lung Cancer
Primary completion
Apr 12, 2025Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT06396065 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT06396065: Phase III Study of AK112 for... | TrialScanner